Press Releases
Search
-
14 Apr 2023
Press Release
Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement
Oxford Nanopore Technologies plc and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.
-
13 Apr 2023
Press Release
bioMérieux receives US FDA 510(k) clearance for the BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini
bioMérieux has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the fast and accurate multiplex PCR*-based BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. bioMérieux will immediately apply for Clinical Laboratory Improvement Amendments (CLIA) waiver for the test.
-
07 Apr 2023
Press Release
SPECIFIC REVEAL™ Rapid AST System, newly renamed VITEK® REVEAL™, submitted to US FDA for 510(k) clearance
bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the VITEK® REVEAL™, formerly known as SPECIFIC REVEAL™ Rapid AST System.
-
05 Apr 2023
Press Release
bioMérieux launches BIOFIRE® FIREWORKS™, a cutting-edge, data-driven software solution
bioMérieux launches BIOFIRE® FIREWORKS™, an innovative and integrated software solution for BIOFIRE® Systems optimizing laboratory services and supporting data-driven decisions. This software is the newest addition to the BIOMÉRIEUX VISION SUITE – the company’s portfolio of Data and IT Solutions supporting increased efficiency and productivity in laboratories worldwide.
-
10 Mar 2023
Press Release
BioFire Defense partners with BARDA to accelerate development of the SPECIFIC REVEAL™ Rapid AST System
BioFire Defense, LLC, has received a contract from the BARDA (Biomedical Advanced Research and Development Authority) to accelerate development of the Specific Diagnostics SPECIFIC REVEAL™ Rapid AST System that can deliver phenotypic results in an average of five and a half hours from positive blood cultures.
-
08 Mar 2023
Press Release
bioMérieux 2022 Financial Results
bioMérieux announced a strong performance in 2022 with robust full-year sales at €3,589 million with a reported growth of +6.3% and an almost neutral organic growth of +0.2%.